Past FSH Society fellows publish research paper “Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD” in Epigenetics that proposes a prognostic marker that can be measured in a relatively accessible tissue to help define the level of disease severity in FSHD
Past FSH Society fellows publish research paper “Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD”
Choice of transcriptional direction from each D4Z4 unit is an additional requirement for DUX4 production and having FSHD
FSHD research teams in Seattle, Rochester and Leiden add to the existing FSHD model loss of heterochromatin at D4Z4 and the presence of a specific haplotype on chromosome 4 are necessary but not sufficient for DUX4 expression in PLoS ONE. Choice of transcriptional direction from each D4Z4 unit is an additional requirement for DUX4 production… Read More »
FSH Society grantees publish new paper “RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy”
FSH Society grantees publish new paper “RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy” in The American Society of Gene & Cell Therapy providing proof-of-principle for RNAi therapy of FSHD through DUX4 inhibition